☆ 4.5 Review

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

NATURE REVIEWS RHEUMATOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Rheumatology

Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials

Yoshiya Tanaka et al.

Summary: Filgotinib, a Janus kinase inhibitor, has shown promise in treating patients with moderately-to-severely active rheumatoid arthritis in clinical studies. It received regulatory approval in Japan and Europe in 2020, though the US FDA requested additional data to assess its potential impact on sperm parameters. Expert opinions on the use of jakinibs for RA treatment will be provided based on basic research and clinical practice.

MODERN RHEUMATOLOGY (2022)

添加到收藏夹

Review Rheumatology

Update on the diagnosis and management of systemic lupus erythematosus

Antonis Fanouriakis et al.

Summary: Systemic lupus erythematosus (SLE) is characterized by clinical heterogeneity, unpredictable course and flares. Diagnosis remains clinical with limited serologic test confirmation, and newer classification criteria offer more accurate classification. Treatment goals focus on patient survival, flare prevention, organ damage prevention, and quality of life optimization. High-intensity immunosuppressive therapy followed by less intensive therapy is typically used to control disease activity in severe cases of SLE.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability

Manabu Narisawa et al.

Summary: This study investigated the function and pathological significance of dendritic cell-derived osteoclasts (DC-OC) in humans, showing that DC-OC have strong bone resorption ability and T-cell stimulating activity, which may contribute to the inflammation and bone destruction in rheumatoid arthritis. Abatacept was found to reduce the T-cell stimulating activity of DC-OC.

BONE (2021)

添加到收藏夹

Review Rheumatology

The role of antirheumatics in patients with COVID-19

Christoffer B. Nissen et al.

Summary: The COVID-19 pandemic has led to over 2 million deaths worldwide, with immune modulators and immunosuppressive drugs proposed as treatments. Further studies are needed to confirm the efficacy and safety, with potential for more clarity on the use of other anti-rheumatic drugs in the next 12 months.

LANCET RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Philip J. Mease et al.

Summary: In patients with active PsA who had inadequate response or intolerance to at least one biologic DMARD, upadacitinib 15 mg and 30 mg were more effective than placebo in improving signs and symptoms of PsA over 24 weeks.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Rheumatology

Why remission is not enough: underlying disease mechanisms in RA that prevent cure

Georg Schett et al.

Summary: This review article addresses the challenges and driving factors in achieving cure for rheumatoid arthritis (RA), highlighting the differences between remission and cure in RA. Strategies targeting these drivers are presented to improve the likelihood of curing RA, complementing current cytokine inhibition therapies.

NATURE REVIEWS RHEUMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19

A. C. Kalil et al.

Summary: Combination treatment with baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study

Yoshiya Tanaka et al.

Summary: The two phase II studies of fostamatinib aimed to evaluate its efficacy and safety in Asian patients with active rheumatoid arthritis. The results showed significant improvements in RA signs and symptoms, with consistent safety and tolerability profiles.

RHEUMATOLOGY (2021)

添加到收藏夹

Article Rheumatology

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

Bernard Combe et al.

Summary: Filgotinib showed significant efficacy in improving signs and symptoms of RA, as well as physical function, while also being well-tolerated in patients with inadequate response to MTX. Filgotinib at a dose of 200mg was non-inferior to adalimumab.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program

Philip G. Conaghan et al.

Summary: Upadacitinib showed significant improvement in remission and low disease activity rates in patients with RA compared to placebo, methotrexate, and adalimumab in five pivotal trials. However, there may be an increased risk of herpes zoster and creatine phosphokinase elevations when compared to methotrexate and adalimumab.

DRUG SAFETY (2021)

添加到收藏夹

Review Medicine, Research & Experimental

Bite of the wolf: innate immune responses propagate autoimmunity in lupus

Sarthak Gupta et al.

Summary: The etiopathogenesis of systemic lupus erythematosus involves a complex interplay between genetic susceptibility factors and the environment, leading to abnormal cell death and immune dysregulation. Recent research has highlighted the important roles of components of the innate immune system, such as neutrophils and interferons, in the pathogenesis of lupus and their potential for novel therapeutic strategies.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Rheumatology

Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting

Yusuke Miyazaki et al.

Summary: BARI demonstrated a similar safety profile and better clinical outcomes compared to TOFA after minimization of selection bias. However, these findings were based on a small population, suggesting the need for further investigation in a properly powered head-to-head trial.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Traves et al.

Summary: JAKinibs, including filgotinib, show varying degrees of potency in inhibiting different JAK-dependent pathways in both healthy and RA blood. Filgotinib demonstrates the highest selectivity for JAK1 pathways compared to other JAKinibs, with less inhibition of JAK2-dependent and JAK3-dependent pathways. Ex vivo pharmacodynamic data from phase 1 healthy volunteers confirms the JAK1 selectivity of filgotinib.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Rheumatology

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

Atul Deodhar et al.

Summary: Tofacitinib demonstrated significantly greater efficacy compared to placebo in treating active ankylosing spondylitis in adults, with good safety profile and no new safety risks identified.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Dermatology

Alopecia Areata New Treatment Options Including Janus Kinase Inhibitors

Caiwei Zheng et al.

DERMATOLOGIC CLINICS (2021)

添加到收藏夹

Review Immunology

JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials

Stephanie Keeling et al.

Summary: This review evaluates the clinical trial data of Janus kinase inhibitors for psoriatic arthritis and spondyloarthritis, showing that these orally administered agents have different selectivity towards JAK1, JAK2, and JAK3, which may impact their efficacy and safety in PsA and SpA. Phase 2 and 3 trials have confirmed the efficacy of these inhibitors in PsA and SpA, with safety profiles comparable to those in rheumatoid arthritis studies.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Dermatology

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King et al.

Summary: The study evaluated the efficacy and safety of two Janus kinase inhibitors, Ritlecitinib and Brepocitinib, in patients with alopecia areata, showing promising results in improving hair loss. However, two patients in the Brepocitinib group experienced serious adverse events.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

Iain B. McInnes et al.

Summary: In a phase 3 trial, both 15mg and 30mg upadacitinib had significantly higher ACR20 response rates at week 12 compared to placebo, with the 30mg dose being superior to adalimumab. Adverse events were more common with upadacitinib than with placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Rheumatology

JAK1 inhibition and inflammatory bowel disease

Clare Harris et al.

Summary: Primary non-response and secondary loss of response are still significant issues with current treatment options for inflammatory bowel disease, highlighting the need for new therapeutic choices. As our understanding of IBD pathogenesis advances, new therapeutic targets are being identified.

RHEUMATOLOGY (2021)

添加到收藏夹

Review Medicine, General & Internal

Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview

Yoshiya Tanaka

Summary: Rheumatoid arthritis is a systemic autoimmune disease that causes bone and cartilage destruction and systemic osteoporosis. Treatments targeting tumor necrosis factor and Janus kinase inhibitors can prevent structural damage, while osteoporosis can be treated with bisphosphonates and anti-receptor activator of the nuclear factor-kappa B ligand antibody. Understanding the mechanisms underlying osteoporosis and joint destruction in rheumatoid arthritis can lead to improved care and new treatments.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Review Rheumatology

Comparative Efficacy and Safety of Peficitinib Versus Tofacitinib and Baricitinib for Treatment of Rheumatoid Arthritis: A Systematic Review and Network Meta-Analysis

Yoshiya Tanaka et al.

Summary: The study indirectly compared the efficacy and safety of Peficitinib, tofacitinib, and baricitinib in rheumatoid arthritis treatment. The results showed that Peficitinib had comparable efficacy to tofacitinib and baricitinib, demonstrating effectiveness in reducing disease activity and slowing joint damage progression, with no notable differences in safety outcomes. Further research is needed to better understand the impact of ethnicity on the efficacy of JAK inhibitors.

RHEUMATOLOGY AND THERAPY (2021)

添加到收藏夹

Meeting Abstract Rheumatology

EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY

A. Armstrong et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise

Silvio Danese et al.

Summary: This review highlights the role of TYK2 signaling in the pathogenesis of inflammatory bowel disease (IBD), the selective inhibition of TYK2 and the potential clinical implications of TYK2 inhibition. While Pan-JAK inhibitors have inconsistent efficacy and toxicities, selective TYK2 inhibitors may offer a more targeted and potentially safer approach in the management of IBD and other immune-mediated inflammatory diseases. Future studies will be crucial in determining the role of selective, allosteric TYK2 inhibition in the management of IBD.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Critical Care Medicine

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial

Vincent C. Marconi et al.

Summary: Although there was no significant reduction in the frequency of disease progression overall, treatment with baricitinib in addition to standard of care (including dexamethasone) had a similar safety profile to that of standard care alone, and was associated with reduced mortality in hospitalised adults with COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

Stanley B. Cohen et al.

Summary: In the phase III clinical trials for RA, patients treated with upadacitinib at 15 mg and 30 mg doses had higher rates of upper respiratory tract infection, nasopharyngitis, and urinary tract infection compared to those on methotrexate and adalimumab. Serious infection rates were similar between upadacitinib 15 mg and adalimumab, but higher than methotrexate, while rates of herpes zoster and CPK elevations were higher with both upadacitinib doses. Rates of deaths, malignancies, MACEs, and VTEs were similar across all treatment groups.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Review Rheumatology

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review

Paul Emery et al.

Summary: Baricitinib 4mg once daily inhibits radiographic joint damage progression in patients with moderate-to-severe RA who are naive to DMARDs or respond inadequately to csDMARDs, including methotrexate, with similar beneficial effects to those observed with adalimumab.

ARTHRITIS RESEARCH & THERAPY (2021)

添加到收藏夹

Review Rheumatology

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Peter Nash et al.

Summary: The use of Janus kinase inhibitors (JAKi) in immune-mediated inflammatory diseases has been extensively reviewed to provide guidance on efficacy and safety. A consensus statement was formed by an expert committee, evaluating 26 key points in six areas, with high levels of agreement and evidence-based recommendations. This consensus offers valuable insights for the practical management of JAKi in clinical practice.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Allergy

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial

Emma Guttman-Yassky et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Review Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

Josef S. Smolen et al.

ANNALS OF THE RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Dermatology

Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

E. L. Simpson et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors

Miguel Nogueira et al.

DRUGS (2020)

添加到收藏夹

Review Rheumatology

State-of-the-art treatment of systemic lupus erythematosus

Yoshiya Tanaka

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2020)

添加到收藏夹

Article Medicine, General & Internal

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Pharmacology & Pharmacy

New and Emerging Therapies for Alopecia Areata

Aunna Pourang et al.

DRUGS (2020)

添加到收藏夹

Article Medicine, Research & Experimental

Mechanism of baricitinib supports artificial intelligence-predicted testing inCOVID-19 patients

Justin Stebbing et al.

EMBO MOLECULAR MEDICINE (2020)

添加到收藏夹

Article Immunology

Translating JAKs to Jakinibs

Massimo Gadina et al.

JOURNAL OF IMMUNOLOGY (2020)

添加到收藏夹

Article Rheumatology

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, PhaseIITrial

Stanley Cohen et al.

ARTHRITIS & RHEUMATOLOGY (2020)

添加到收藏夹

Article Rheumatology

Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Michael F. Robinson et al.

ARTHRITIS & RHEUMATOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

JAK-STAT pathway targeting for the treatment of inflammatory bowel disease

Azucena Salas et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

Faping Wang et al.

MAYO CLINIC PROCEEDINGS (2020)

添加到收藏夹

Article Medicine, General & Internal

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

Andrea Rubbert-Roth et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Rheumatology

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Stanley B. Cohen et al.

RMD OPEN (2020)

添加到收藏夹

Review Immunology

Rheumatoid arthritis

Yoshiya Tanaka

INFLAMMATION AND REGENERATION (2020)

添加到收藏夹

Article Rheumatology

Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study

Ajinkya Pawar et al.

LANCET RHEUMATOLOGY (2020)

添加到收藏夹

Editorial Material Rheumatology

The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?

Yoshiya Tanaka

RHEUMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Josef S. Smolen et al.

LANCET (2019)

添加到收藏夹

Article Rheumatology

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Katie Bechman et al.

RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)

Yoshiya Tanaka et al.

ANNALS OF THE RHEUMATIC DISEASES (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?

Silvio Danese et al.

GUT (2019)

添加到收藏夹

Article Medicine, General & Internal

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial

Mark C. Genovese et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

添加到收藏夹

Article Allergy

Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis

Ana B. Pavel et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

添加到收藏夹

Review Rheumatology

New therapies for systemic lupus erythematosus - past imperfect, future tense

Grainne Murphy et al.

NATURE REVIEWS RHEUMATOLOGY (2019)

添加到收藏夹

Article Cell Biology

Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain

James R. Burke et al.

SCIENCE TRANSLATIONAL MEDICINE (2019)

添加到收藏夹

Article Rheumatology

Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases

Yoshiya Tanaka et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)

添加到收藏夹

Article Rheumatology

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial

Roy Fleischmann et al.

ARTHRITIS & RHEUMATOLOGY (2019)

添加到收藏夹

Review Rheumatology

Bedside to bench: defining the immunopathogenesis of psoriatic arthritis

Arlene Bravo et al.

NATURE REVIEWS RHEUMATOLOGY (2019)

添加到收藏夹

Review Rheumatology

The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis

Joachim Sieper et al.

NATURE REVIEWS RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Pathophysiology, assessment and treatment of psoriatic dactylitis

Dennis McGonagle et al.

NATURE REVIEWS RHEUMATOLOGY (2019)

添加到收藏夹

Review Rheumatology

Clinical significance of Janus Kinase inhibitor selectivity

Ernest H. Choy

RHEUMATOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

Desiree van der Heijde et al.

LANCET (2019)

添加到收藏夹

Article Rheumatology

Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

Juergen Wollenhaupt et al.

ARTHRITIS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Rheumatology

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations

Iain B. McInnes et al.

ARTHRITIS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Rheumatology

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial

Richard A. Furie et al.

LANCET RHEUMATOLOGY (2019)

添加到收藏夹

Article Rheumatology

The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE

Niklas Hagberg et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

添加到收藏夹

Review Medicine, General & Internal

Psoriatic arthritis 2 Clinical management of psoriatic arthritis

Filip Van den Bosch et al.

LANCET (2018)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Mark C. Genovese et al.

LANCET (2018)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace et al.

LANCET (2018)

添加到收藏夹

Article Immunology

Janus Kinase inhibitor Baricitinib Modulates human innate and adaptive immune system

Satoshi Kubo et al.

FRONTIERS IN IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Rheumatoid arthritis

Josef S. Smolen et al.

NATURE REVIEWS DISEASE PRIMERS (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials

Julian Panes et al.

GUT (2017)

添加到收藏夹

Article Medicine, General & Internal

Pathogenetic insights from the treatment of rheumatoid arthritis

Iain B. McInnes et al.

LANCET (2017)

添加到收藏夹

Review Biotechnology & Applied Microbiology

JAK inhibition as a therapeutic strategy for immune and inflammatory diseases

Daniella M. Schwartz et al.

NATURE REVIEWS DRUG DISCOVERY (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Current and emerging therapeutic targets for IBD

Markus F. Neurath

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2017)

添加到收藏夹

Review Rheumatology

Enthesitis: from pathophysiology to treatment

Georg Schett et al.

NATURE REVIEWS RHEUMATOLOGY (2017)

添加到收藏夹

Review Rheumatology

The emerging safety profile of JAK inhibitors in rheumatic disease

Kevin L. Winthrop

NATURE REVIEWS RHEUMATOLOGY (2017)

添加到收藏夹

Review Medicine, General & Internal

Psoriatic Arthritis

Christopher T. Ritchlin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

P. Mease et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

Dafna Gladman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

Peter C. Taylor et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Immunology

Mechanisms and consequences of Jak-STAT signaling in the immune system

Alejandro V. Villarino et al.

NATURE IMMUNOLOGY (2017)

添加到收藏夹

Article Dermatology

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

K. A. Papp et al.

BRITISH JOURNAL OF DERMATOLOGY (2016)

添加到收藏夹

Review Medicine, General & Internal

Rheumatoid arthritis

Josef S. Smolen et al.

LANCET (2016)

添加到收藏夹

Review Rheumatology

Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE

Thomas Doerner et al.

NATURE REVIEWS RHEUMATOLOGY (2016)

添加到收藏夹

Review Immunology

Understanding inflammatory bowel disease via immunogenetics

Katrina M. de Lange et al.

JOURNAL OF AUTOIMMUNITY (2015)

添加到收藏夹

Article Rheumatology

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

Satoshi Kubo et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

添加到收藏夹

Article Rheumatology

Janus kinase inhibitors in autoimmune diseases

John J. O'Shea et al.

ANNALS OF THE RHEUMATIC DISEASES (2013)

添加到收藏夹

Article Rheumatology

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study

Desiree van der Heijde et al.

ARTHRITIS AND RHEUMATISM (2013)

添加到收藏夹

Review Medicine, General & Internal

MECHANISMS OF DISEASE JAKs and STATs in Immunity, Immunodeficiency, and Cancer

John J. O'Shea et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Rheumatology

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis

Y. Tanaka et al.

ANNALS OF THE RHEUMATIC DISEASES (2012)

添加到收藏夹

Article Rheumatology

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

Keisuke Maeshima et al.

ARTHRITIS AND RHEUMATISM (2012)

添加到收藏夹

Review Biochemistry & Molecular Biology

Taming lupus-a new understanding of pathogenesis is leading to clinical advances

Zheng Liu et al.

NATURE MEDICINE (2012)

添加到收藏夹

Article Immunology

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

Kamran Ghoreschi et al.

JOURNAL OF IMMUNOLOGY (2011)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Sandra V. Navarra et al.

LANCET (2011)

添加到收藏夹

Article Rheumatology

Phase II Study of Tofacitinib (CP-690,550) Combined With Methotrexate in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Yoshiya Tanaka et al.

ARTHRITIS CARE & RESEARCH (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor

PS Changelian et al.

SCIENCE (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.